Rabies Treatment Market Research Information Type (Furious Rabies, Paralytic Rabies and others), By Treatment (Rabies Immunoglobulin, Brain Tissue Vaccines, Tissue Culture Vaccines and others), End Users (Hospital, Clinics) - Forecast till 2032

Global Rabies Treatment Market Overview

The Rabies Treatment Market Size was valued at USD 1.16 Billion in 2023. The Global Rabies Treatment industry is projected to grow from USD 1.23 Billion in 2024 to USD 1.95 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 7.10% during the forecast period (2024 - 2032).

Rabies is a deadly virus that usually spreads from the saliva of infected/rabid animals. Animals that are most likely to transmit rabies include bats, raccoons, coyotes, foxes, and skunks. In developing countries, stray dogs are the most likely to get infected with rabies. It is stated by the WHO that rabies infection is responsible for tens of thousands of deaths every year, especially, in Asia and Africa. Signs and symptoms of rabies include headache, nausea, vomiting, confusion, hyperactivity, difficulty in swallowing, agitation, anxiety, hallucinations, insomnia, partial paralysis, hydrophobia (fear of water), and excessive salivation. Rabies virus basically infects the central nervous system and salivary glands which ultimately leads to death. 

Rabies Treatment Market Trends

Treatment by vaccination is the best and most effective method in treating as well as preventing rabies. One of the approved and effective methods against rabies is when inactivated rabies vaccine is combined with rabies immunoglobulin. Rabies is diagnosed by detecting proteins present on the surface of rabies virus using samples of blood, saliva samples, and skin. To get rid of this deadly disease, various government, and privately held organizations actively participate to make people aware of the current scenario. For instance, the Food and Agriculture Organization (FAO), Global Alliance for Rabies Control (GARC), WHO, and International Organisation for Animal Health (OIE) teamed up together in 2015 to achieve strategic plan of "Zero human Rabies deaths by 2030". The main aim of this initiative is to prioritize healthcare investments in rabies control and coordinate the rabies-elimination efforts.

Notably, increasing population of stray dogs, monkeys and other rabid animals is the key factor driving the rabies treatment market. According to the WHO, Dogs are the main source of rabies infection and subsequent deaths, contributing to nearly 99% of all rabies transmissions to humans.

Various other factors such as, production of contamination-free vaccines using novel culture media, regulatory examinations, and conduction of awareness program by government continuously motivate marketers to come up with new drugs, and vaccines to treat rabies. Sanofi and Novartis are the key players in the rabies treatment market. Both the companies manufacture prophylactic vaccines. Sanofi develops, and markets Imovax Rabies vaccine whereas Novartis manufactures RabAvert vaccine.

Despite these drivers, high cost of rabies treatment, and poor healthcare expenditure in developing countries may hamper the growth of the market to a great extent. Despite the great economic development in the Asia Pacific region, some part of the region are facing inadequate health expenditure due to unequal distribution of resources.

Rabies Treatment Market Segments Insights

The rabies treatment market is segmented on the basis of type of rabies, type of treatment, and end users.

Rabies Treatment Type of Rabies Insights

On the basis of type of rabies, rabies treatment market is segmented into furious rabies, paralytic rabies and others

Rabies Treatment Type Insights

On the basis of type of treatment, rabies treatment market is classified into rabies immunoglobin vaccine, bran tissue vaccine, tissue culture and others.

Rabies Treatment End User Insights

On the basis of end-users, rabies treatment market is segmented into hospitals, clinics, epidemic prevention centres and others.

Rabies Treatment Market Regional Insights

On the regional basis, the rabies treatment market is segmented into America, Europe, Asia Pacific and the Middle East & Africa.

The Americas dominate the rabies treatment market owing to the remarkable use of the vaccine for preventing diseases and favorable conditions for research and development. In America, rabies vaccination programs have eliminated domestic dogs as reservoirs of rabies virus. According to the data suggested by Centers for Disease Control and Prevention, an estimated health costs associated with rabies disease detection, and control have risen, exceeding $300 million annually

Europe is the second largest market for rabies treatment market followed by Asia Pacific. Owing to the availability of funds for research and development activities and growing emphasis on research for treating diseases. Asia Pacific shows the fastest growth in this market due to an increase in prevalence of communicable diseases. Particularly, India and China are expected to be an emerging and the fastest growing market.

The Middle East & Africa has the lowest market for rabies treatment due to lack of technical knowledge and poor medical facilities.

Key Players

Some of key the players in the rabies treatment market are 

• Sanofi (France)


• Merck & Co. Inc. 


• CSC Pharmaceuticals International 


• Pfizer (U.S.)


• VBI Vaccines Inc. (U.S.)


• Taj Pharmaceuticals (India)


• Bio Med Pvt. Ltd.


• Bavarian Nordic(U.S.)


• Solvay(U.S.)


• Informa plc.(U.S.)